Arrowhead Pharmaceuticals Reports Underwhelming Data From Inherited Disease Study

  • Takeda Pharmaceutical Co Ltd TAK and Arrowhead Pharmaceuticals Inc ARWR announced topline results from the Phase 2 SEQUOIA study of fazirsiran (TAK-999/ARO-AAT) for liver disease associated with alpha-1 antitrypsin deficiency (AATD-LD). 
  • Patients receiving 25 mg, 100 mg, or 200 mg of fazirsiran who had baseline fibrosis (n=16) demonstrated a dose-dependent mean reduction in serum mutant alpha-1 antitrypsin protein (Z-AAT) concentration at week 48 of 74%, 89%, and 94%, respectively. 
  • All three doses reduced total liver Z-AAT with a median reduction of 94%. 
  • In addition, PAS-D globule burden, a histological measure of Z-AAT accumulation, was reduced from a baseline mean of 5.9 to a post-baseline mean of 2.3 at the postbaseline liver biopsy visit. 
  • Improvement in portal inflammation was observed in 42% of patients, while only 7% showed worsening. 
  • Lastly, 50% of patients achieved an improvement in fibrosis of at least one point by METAVIR stage.
  • In contrast, by week 48, patients receiving a placebo who had baseline fibrosis (n=9) saw no meaningful changes from baseline in serum Z-AAT, a 26% increase in liver Z-AAT, and no meaningful change in PAS-D globule burden.
  • No placebo patients experienced an improvement in portal inflammation. 
  • 44% experienced worsening, 22% of placebo patients experienced worsening, while 38% experienced an improvement in fibrosis at the postbaseline liver biopsy visit. 
  • Fazirsiran has been well tolerated, with treatment-emergent adverse events reported to date generally well balanced between fazirsiran and placebo groups. 
  • Price Action: ARWR shares are down 22.60% at $28.95 on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!